Skip Navigation


Human Molecular Genetics Advance Access originally published online on July 21, 2004
Human Molecular Genetics 2004 13(18):2031-2042; doi:10.1093/hmg/ddh222
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/18/2031    most recent
ddh222v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grohmann, K.
Right arrow Articles by Sendtner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grohmann, K.
Right arrow Articles by Sendtner, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol. 13, No. 18 © Oxford University Press 2004; all rights reserved

Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1)

Katja Grohmann1,3, Wilfried Rossoll1, Igor Kobsar2, Bettina Holtmann1, Sibylle Jablonka1, Carsten Wessig2, Gisela Stoltenburg-Didinger4, Utz Fischer5, Christoph Hübner3, Rudolf Martini2 and Michael Sendtner1,*

1Institute for Clinical Neurobiology and 2Department of Neurology, University of Wuerzburg, D-97080 Wuerzburg, Germany, 3Department of Neuropediatrics and 4Institute for Neuropathology, Charité University Medical Center, D-13353 Berlin, Germany and 5Institute of Biochemistry, University of Wuerzburg, D-97074 Wuerzburg, Germany

Received May 5, 2004; Revised June 30, 2004; Accepted July 8, 2004

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is caused by recessive mutations of the IGHMBP2 gene. The role of IGHMBP2 (immunoglobulin µ-binding protein 2) in the pathomechanism of motor neuron disease is unknown. We have generated antibodies against Ighmbp2 and showed that low levels of Ighmbp2 immunoreactivity are present in the nucleus of spinal motor neurons and high levels in cell bodies, axons and growth cones. Ighmbp2 protein levels are strongly reduced in neuromuscular degeneration (nmd) mice, the mouse model of SMARD1. Mutant mice show severe motor neuron degeneration before first clinical symptoms become apparent. The loss of motor neuron cell bodies in lumbar spinal cord is followed by axonal degeneration in corresponding nerves such as the femoral quadriceps and sciatic nerve and loss of axon terminals at motor endplates. Motor neuron degeneration and clinical symptoms then slowly progress until the mice die at the age of 3–4 months. In addition, myopathic changes seem to contribute to muscle weakness and especially to respiratory failure, which is characteristic of the disorder in humans. Cultured motor neurons from embryonic nmd mice did not show any abnormality with respect to survival, axonal growth or growth cone size, thus differing from motor neurons derived from, e.g. Smn (survival motor neuron) deficient mice, the model of spinal muscular atrophy (SMA). Our data suggest that the pathomechanism in SMARD1 is clearly distinct from other motor neuron diseases such as classic SMA.

* To whom correspondence should be addressed. Tel: +49 93120149771; Fax: +49 93120149788; Email: sendtner_m{at}klinik.uni-wuerzburg.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. de Planell-Saguer, D. G. Schroeder, M. C. Rodicio, G. A. Cox, and Z. Mourelatos
Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery
Hum. Mol. Genet., June 15, 2009; 18(12): 2115 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
U.-P. Guenther, L. Handoko, B. Laggerbauer, S. Jablonka, A. Chari, M. Alzheimer, J. Ohmer, O. Plottner, N. Gehring, A. Sickmann, et al.
IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1)
Hum. Mol. Genet., April 1, 2009; 18(7): 1288 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
A. M. Kaindl, U.-P. Guenther, S. Rudnik-Schoneborn, R. Varon, K. Zerres, M. Schuelke, C. Hubner, and K. von Au
Spinal Muscular Atrophy With Respiratory Distress Type 1 (SMARD1)
J Child Neurol, February 1, 2008; 23(2): 199 - 204.
[Abstract] [PDF]

Home page
 Hum Mol GenetHome page
S. Corti, F. Locatelli, D. Papadimitriou, C. Donadoni, R. Del Bo, M. Crimi, A. Bordoni, F. Fortunato, S. Strazzer, G. Menozzi, et al.
Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1
Hum. Mol. Genet., January 15, 2006; 15(2): 167 - 187.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
T. P. Maddatu, S. M. Garvey, D. G. Schroeder, W. Zhang, S.-Y. Kim, A. I. Nicholson, C. J. Davis, and G. A. Cox
Dilated cardiomyopathy in the nmd mouse: transgenic rescue and QTLs that improve cardiac function and survival
Hum. Mol. Genet., November 1, 2005; 14(21): 3179 - 3189.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. Ruiz, J. Lin, A. Forgie, D. Foletti, D. Shelton, A. Rosenthal, and L. Tabares
Treatment with trkC agonist antibodies delays disease progression in neuromuscular degeneration (nmd) mice
Hum. Mol. Genet., July 1, 2005; 14(13): 1825 - 1837.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.